Pubblicazioni

Autori:

Frisoni, Giovanni B; Festari, Cristina; Massa, Federico; Cotta Ramusino, Matteo; Orini, Stefania; Aarsland, Dag; Agosta, Federica; Babiloni, Claudio; Borroni, Barbara; Cappa, Stefano F; Frederiksen, Kristian S; Froelich, Lutz; Garibotto, Valentina; Haliassos, Alexander; Jessen, Frank; Kamondi, Anita; Kessels, Roy Pc; Morbelli, Silvia D; O'Brien, John T; Otto, Markus; Perret-Liaudet, Armand; Pizzini, Francesca B; Vandenbulcke, Mathieu; Vanninen, Ritva; Verhey, Frans; Vernooij, Meike W; Yousry, Tarek; Boada Rovira, Mercè; Dubois, Bruno; Georges, Jean; Hansson, Oskar; Ritchie, Craig W; Scheltens, Philip; van der Flier, Wiesje M; Nobili, Flavio

Titolo:

European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

LANCET NEUROLOGY

ISSN Rivista:

1474-4422

N° Volume:

23

Numero o Fascicolo:

3

Intervallo pagine:

302-312

Parole chiave:

Alzheimer Disease; Biomarkers; Consensus; Europe; Humans; Societies, Scientific

Breve descrizione dei contenuti:

: The recent commercialisation of the first disease-modifying drugs for Alzheimer's disease emphasises the need for consensus recommendations on the rational use of biomarkers to diagnose people with suspected neurocognitive disorders in memory clinics. Most available recommendations and guidelines are either disease-centred or biomarker-centred. A European multidisciplinary taskforce consisting of 22 experts from 11 European scientific societies set out to define the first patient-centred diagnostic workflow that aims to prioritise testing for available biomarkers in individuals attending memory clinics. After an extensive literature review, we used a Delphi consensus procedure to identify 11 clinical syndromes, based on clinical history and examination, neuropsychology, blood tests, structural imaging, and, in some cases, EEG. We recommend first-line and, if needed, second-line testing for biomarkers according to the patient's clinical profile and the results of previous biomarker findings. This diagnostic workflow will promote consistency in the diagnosis of neurocognitive disorders across European countries.

Id prodotto:

137910

Handle IRIS:

11562/1119674

ultima modifica:

6 aprile 2024

Citazione bibliografica:

Frisoni, Giovanni B; Festari, Cristina; Massa, Federico; Cotta Ramusino, Matteo; Orini, Stefania; Aarsland, Dag; Agosta, Federica; Babiloni, Claudio; Borroni, Barbara; Cappa, Stefano F; Frederiksen, Kristian S; Froelich, Lutz; Garibotto, Valentina; Haliassos, Alexander; Jessen, Frank; Kamondi, Anita; Kessels, Roy Pc; Morbelli, Silvia D; O'Brien, John T; Otto, Markus; Perret-Liaudet, Armand; Pizzini, Francesca B; Vandenbulcke, Mathieu; Vanninen, Ritva; Verhey, Frans; Vernooij, Meike W; Yousry, Tarek; Boada Rovira, Mercè; Dubois, Bruno; Georges, Jean; Hansson, Oskar; Ritchie, Craig W; Scheltens, Philip; van der Flier, Wiesje M; Nobili, Flavio, European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders «LANCET NEUROLOGY» , vol. 23 , n. 3 , 2024 , pp. 302-312

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo